BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24384769)

  • 1. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
    Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
    Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer.
    Mroczko B; Lukaszewicz-Zając M; Gryko M; Kędra B; Szmitkowski M
    Folia Histochem Cytobiol; 2011; 49(1):125-31. PubMed ID: 21526499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
    Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
    Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
    Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
    Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
    Li L; Zhang S; Lin H; Lin JY
    Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
    Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
    Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
    Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
    Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.
    Groblewska M; Mroczko B; Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kędra B; Kemona A; Szmitkowski M
    Tumour Biol; 2014 Apr; 35(4):3793-802. PubMed ID: 24395652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
    Zhang S; Li L; Lin JY; Lin H
    World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
    Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
    Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between matrix metalloproteinases-2 and tissue inhibitor of metalloproteinase-2 expression, metastatic potential and tumor angiogenesis in synovial sarcoma and its prognostic significance].
    Sun BC; Sun Y; Zhao XL; Wang J; Wang X; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):155-8. PubMed ID: 16630504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.
    Wang PH; Ko JL; Yang SF; Tsai HT; Tee YT; Han CP; Lin LY; Chen SC; Shih YT
    Reprod Sci; 2011 Aug; 18(8):798-808. PubMed ID: 21422052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
    Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
    Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.